Oncotyrol is an international partnership located in Innsbruck, Austria that aims to accelerate the development of personalized cancer therapies. It brings together academic researchers from local universities and international partners like Harvard Medical School to collaborate with industry partners like Roche and Novartis. The goal is to apply scientific expertise in oncology to generate patents, licenses and publications to help translate research into commercial treatments. The close collaboration is intended to benefit patients by saving time, increasing efficiency and innovation potential for the health system. The partnership is funded for four years with a 24 million euro budget from national and regional sources.